Millan Maria T, Berquist William E, So Sam K, Sarwal Minnie M, Wayman Karen I, Cox Kenneth L, Filler Guido, Salvatierra Oscar, Esquivel Carlos O
Stanford University School of Medicine, Palo Alto, CA 94304, USA.
Transplantation. 2003 Nov 27;76(10):1458-63. doi: 10.1097/01.TP.0000084203.76110.AC.
Combined liver-kidney transplantation is the definitive treatment for end-stage renal disease caused by primary hyperoxaluria type I (PH1). The infantile form is characterized by renal failure early in life, advanced systemic oxalosis, and a formidable mortality rate. Although others have reported on overall results of transplantation for PH1 covering a wide age spectrum, none has specifically addressed the high-risk infantile form of the disease.
Six infants with PH1 underwent simultaneous liver-kidney transplantation at our center between May 1994 and August 1998. Diagnosis was made at 5.2+/-3.3 months of age, they were on dialysis for 11.8+/-2.3 months, and they underwent transplantation at 14.8+/-3.0 months of age when they weighed 10.6+/-1.7 kg.
At a mean follow-up of 6.4+/-1.7 years (range, 3.9-8.1 years), we report 100% patient and kidney allograft survival. There were no cases of acute tubular necrosis. Long-term kidney allograft function remained stable in all patients, with serum creatinine values of less than 1.1 mg/dL and a mean creatinine clearance of 99 mL/min/1.73 m2 at follow-up. Those who received combined hemodialysis and peritoneal dialysis pretransplant had lower posttransplant urinary oxalate values than those receiving peritoneal dialysis alone. There was improvement in growth and psychomotor and mental developmental scores after transplantation.
Combined liver-kidney transplantation for the infantile presentation of PH1 is associated with excellent outcome when the approach includes early diagnosis and early combined transplantation, aggressive pretransplant dialysis, and avoidance of posttransplant renal dysfunction.
肝肾联合移植是治疗I型原发性高草酸尿症(PH1)所致终末期肾病的确定性治疗方法。婴儿型的特点是在生命早期出现肾衰竭、晚期全身草酸沉积症以及极高的死亡率。尽管其他人报道了涵盖广泛年龄范围的PH1移植总体结果,但尚无专门针对该疾病高风险婴儿型的报道。
1994年5月至1998年8月期间,6例PH1婴儿在我们中心接受了同期肝肾联合移植。诊断时的年龄为5.2±3.3个月,他们接受透析11.8±2.3个月,在14.8±3.0个月龄、体重10.6±1.7 kg时接受移植。
平均随访6.4±1.7年(范围3.9 - 8.1年),我们报告患者和肾移植存活率均为100%。无急性肾小管坏死病例。所有患者的长期肾移植功能保持稳定,随访时血清肌酐值低于1.1 mg/dL,平均肌酐清除率为99 mL/min/1.73 m²。移植前接受血液透析和腹膜透析联合治疗的患者,其移植后尿草酸值低于仅接受腹膜透析的患者。移植后生长、精神运动和智力发育评分均有改善。
对于婴儿型PH1,当治疗方法包括早期诊断和早期联合移植、积极的移植前透析以及避免移植后肾功能障碍时,肝肾联合移植的预后良好。